R&D Work on Biogenerics
Research and development work started at Vanderbilt, Nashville, Tennessee.
Virchow Biotech Private Limited
Home / Milestones
Research and development work started at Vanderbilt, Nashville, Tennessee.
Virchow Biotech was incorporated in India. R&D assets were transferred to India.
Construction of the manufacturing facility at Gagillapur began.
Virchow’s first Biogeneric approval for PDGF-BB.
Additional Biogeneric Approvals for Teriparatide, PEG-Interferon. Customer base expansion.
Expanded export base, diversified product range, and commercialization of Rasburicase.
PICS Approval (Ukraine), INVIMA Approval, USFDA Approval obtained.
Acquired Silvasorb product portfolio from Halyard Inc. and started vaccine development.
PIC/s Approval Malaysia. Unit 3, 4, and 5 became operational.
Innovation Begins
Research and development work started at Vanderbilt, Nashville, Tennessee.
Foundation Laid
Virchow Biotech was incorporated in India. R&D assets were transferred to India.
Growth Initiated
Construction of the manufacturing facility at Gagillapur began.
Breakthrough Achieved
Virchow’s first Biogeneric approval for PDGF-BB.
Portfolio Grows
Additional Biogeneric Approvals for Teriparatide, PEG-Interferon. Customer base expansion.
Global Reach
Expanded export base, diversified product range, and commercialization of Rasburicase.
Standards Met
PICS Approval (Ukraine), INVIMA Approval, USFDA Approval obtained.
Strategic Move
Acquired Silvasorb product portfolio from Halyard Inc. and started vaccine development.
Capacity Boost
PIC/s Approval Malaysia. Unit 3, 4, and 5 became operational.
Automated page speed optimizations for fast site performance